Navigation Links
Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
Date:9/13/2007

CAMBRIDGE, Mass., Sept. 13 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference will be webcast live and may be accessed by visiting the Investors section of the Company's website, http://www.millennium.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )

The presentation will include an overview of the Company, an update on clinical trials for VELCADE(R) (bortezomib) for Injection and other product candidates, and a review of upcoming milestones. The presentation will be delivered at 9:20 a.m. ET (2:20 p.m. GMT) on Thursday, September 20, 2007 from the Merrill Lynch Financial Centre in London, England. The presentation will be archived for 30 days.

About Millennium

Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has a robust clinical development pipeline of product candidates. The Company's research, development and commercialization activities are focused in two therapeutic areas: oncology and inflammation. By applying its knowledge of the human genome, understanding of disease mechanisms and industrialized drug discovery platform, Millennium is developing an exciting pipeline of innovative product candidates. The Company's website is http://www.millennium.com.

Editors' Note: This press release is also available under the Media section of the Company's website at: http://www.millennium.com.

Contact:

Kyle Kuvalanka

(617) 761-4734


'/>"/>
SOURCE Millennium Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Ethanol plant builder to expand Merrill facility
2. World Class Life Science and Pharmaceutical Companies Leverage DoveBid s Global Reach for Asset Management and Disposition
3. The state of global biotech: An Ernst & Young perspective
4. Doyle announces new energy, global warming policies
5. Lucigen Corp. enters global licensing agreement
6. Global information firm reaches diverse markets
7. Work-life imbalance - A global problem getting worse
8. Leading global Big Pharma companies of 2005
9. Learning to swim in the global talent pool
10. Federal and global guidelines on stem cell research offer a level playing field
11. Midwest life-science company Perrigo globalizes under the radar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... October 11, 2017 , ... At its national board meeting ... I. Sheikh, the co-founder, CEO and chief research scientist of Minnesota-based Advanced Space ... membership in ARCS Alumni Hall of Fame . ASTER Labs is a ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading provider ... nationwide oncology Clinical Nurse Educator (CNE) network, which will launch ... for communication among health care professionals to enhance the patient ... office staff, and other health care professionals to help women ... cancer. ...
(Date:10/10/2017)... DIEGO, CALIF. (PRWEB) , ... October 10, 2017 , ... ... as part of its corporate rebranding initiative announced today. The bold new look ... its reach, as the company moves into a significant growth period. , It will ...
(Date:10/10/2017)... SomaGenics announced the receipt of a Phase ... (Single Cell), expected to be the first commercially available ... from single cells using NGS methods. The NIH,s recent ... development of approaches to analyze the heterogeneity of cell ... for measuring levels of mRNAs in individual cells have ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... 2017 Today HYPR Corp. , leading ... component of the HYPR platform is officially FIDO® ... security architecture that empowers biometric authentication across Fortune 500 ... secured over 15 million users across the financial services ... home product suites and physical access represent a growing ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
Breaking Biology News(10 mins):